glp-1 masld The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis Glucagon-like peptide-1 receptor agonists improve

Moreover, a decrease in atherosclerotic cardiovascular disease (ASCVD) has been found in people treated with semaglutide who were obese or overweight, but, this trend was not statistically significant [28]

Reduced appetite = reduced intake = increased risk of missing key nutrients like: Protein Iron, calcium, magnesium, zinc, potassium, choline, folate

Hair Loss Reports What the Data Actually Shows Published TRIUMPH-1 and TRIUMPH-4 readouts have not flagged hair loss as a primary adverse event of interest

Resources We Trust Mayo Clinic: Supporting Weight-Loss Medications With Adequate, Tailored Nutrition National Institute of Diabetes and Digestive and Kidney Diseases: Prescription Medications to Treat Overweight & Obesity Massachusetts General Hospital: Fitness for People Taking GLP-1 Agonists: A Comprehensive Guide Cleveland Clinic: This Is How to Lose Weight the Right Way and Keep It Off Yale Medicine: Why Your Cardiologist May Prescribe Semaglutide (Wegovy) Vosoughi K et al